CA2729663A1 - Compounds having antiviral properties - Google Patents

Compounds having antiviral properties Download PDF

Info

Publication number
CA2729663A1
CA2729663A1 CA2729663A CA2729663A CA2729663A1 CA 2729663 A1 CA2729663 A1 CA 2729663A1 CA 2729663 A CA2729663 A CA 2729663A CA 2729663 A CA2729663 A CA 2729663A CA 2729663 A1 CA2729663 A1 CA 2729663A1
Authority
CA
Canada
Prior art keywords
group
3alkylene
pyrido
morpholin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2729663A
Other languages
English (en)
French (fr)
Inventor
John Joseph Deadman
Eric Dale Jones
Giang Thanh Le
David Ian Rhodes
Neeranat Thienthong
Nicholas Andrew Van De Graff
Lisa Jane Winfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903407A external-priority patent/AU2008903407A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of CA2729663A1 publication Critical patent/CA2729663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2729663A 2008-07-02 2009-07-02 Compounds having antiviral properties Abandoned CA2729663A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2008903407 2008-07-02
AU2008903407A AU2008903407A0 (en) 2008-07-02 Compounds having antiviral properties
US16193109P 2009-03-20 2009-03-20
US61/161,931 2009-03-20
PCT/AU2009/000858 WO2010000032A1 (en) 2008-07-02 2009-07-02 Compounds having antiviral properties

Publications (1)

Publication Number Publication Date
CA2729663A1 true CA2729663A1 (en) 2010-01-07

Family

ID=41465417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2729663A Abandoned CA2729663A1 (en) 2008-07-02 2009-07-02 Compounds having antiviral properties

Country Status (14)

Country Link
US (2) US8318732B2 (zh)
EP (2) EP2212324B1 (zh)
JP (1) JP5535204B2 (zh)
CN (1) CN102143962B (zh)
AU (1) AU2009266421B2 (zh)
BR (1) BRPI0913934A2 (zh)
CA (1) CA2729663A1 (zh)
ES (1) ES2459046T3 (zh)
IL (1) IL210207A0 (zh)
MX (1) MX2011000149A (zh)
NZ (1) NZ590126A (zh)
PL (1) PL2212324T3 (zh)
SG (1) SG192452A1 (zh)
WO (1) WO2010000032A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000030A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
FR2947272B1 (fr) * 2009-06-29 2014-09-26 Univ Paris Curie Utilisation d'arn interferents pour le traitement d'une infection par le vih
KR20120130185A (ko) * 2010-02-26 2012-11-29 니뽄 다바코 산교 가부시키가이샤 １,３,４,８―테트라히드로―２Ｈ―피리도［１,２―ａ］피라진 유도체 및 그의 ＨＩＶ 인테그라제 저해제로서의 이용
US8846659B2 (en) * 2010-12-10 2014-09-30 Bristol-Myers Squibb Company HIV integrase inhibitors
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
KR101957178B1 (ko) * 2014-04-28 2019-03-12 지앙수 카니온 파마수티컬 씨오., 엘티디. 항엔테로바이러스71 티아디아졸리딘 유도체
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
US20180096362A1 (en) * 2016-10-03 2018-04-05 Amy Ashley Kwan E-Commerce Marketplace and Platform for Facilitating Cross-Border Real Estate Transactions and Attendant Services
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
BR112019027719A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
JP7421507B2 (ja) 2018-06-27 2024-01-24 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
SI3986561T1 (sl) * 2019-06-19 2024-04-30 VIIV Healthcare UK (No.5) Limited Pirido(2,3-d)pirimidinski derivati kot zaviralci podvojevanja virusa humane imunske pomanjkljivosti
EP4069694A1 (en) 2019-12-02 2022-10-12 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530520T1 (de) * 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
JP5094725B2 (ja) * 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
JP2008019644A (ja) 2006-07-13 2008-01-31 Hitoshi Koide 石油または天然ガスの増進回収方法及びその増進回収システム
DE602007012308D1 (de) * 2006-12-22 2011-03-10 Avexa Ltd Bicyclische pyrimidinone und deren verwendung
EP2291377B1 (en) 2008-07-02 2015-02-18 Avexa Limited Imidazopyrimidinones and uses thereof

Also Published As

Publication number Publication date
BRPI0913934A2 (pt) 2015-10-20
EP2212324A1 (en) 2010-08-04
US20130059865A1 (en) 2013-03-07
WO2010000032A1 (en) 2010-01-07
JP5535204B2 (ja) 2014-07-02
SG192452A1 (en) 2013-08-30
US20110039842A1 (en) 2011-02-17
CN102143962B (zh) 2015-03-11
US8563562B2 (en) 2013-10-22
AU2009266421A1 (en) 2010-01-07
PL2212324T3 (pl) 2014-11-28
IL210207A0 (en) 2011-03-31
AU2009266421B2 (en) 2013-07-11
EP2759544A1 (en) 2014-07-30
CN102143962A (zh) 2011-08-03
US8318732B2 (en) 2012-11-27
NZ590126A (en) 2012-11-30
JP2011526248A (ja) 2011-10-06
ES2459046T3 (es) 2014-05-07
EP2212324B1 (en) 2014-03-26
MX2011000149A (es) 2011-02-24
EP2212324A4 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2212324B1 (en) Compounds having antiviral properties
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
CA2729656A1 (en) Imidazopyrimidinones and uses thereof
WO2008157273A1 (en) Chemical compounds
US8426405B2 (en) Thiazopyrimidinones and uses thereof
KR20120096076A (ko) 스핑고신 키나아제 저해제
US8569345B2 (en) Compounds and compositions as LXR modulators
US7998954B2 (en) Pyrimidodiazepinone derivative
ES2358550T3 (es) Pirimidinonas bicíclicas y sus usos.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140625

FZDE Discontinued

Effective date: 20160704